Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | ePRO monitoring in advanced solid tumors: results from PRO-MOTE

Naomi Kiyota • 1 Jun 2026
ASCO 2026
General
PRO-MOTE

Naomi Kiyota, MD, Kobe University Hospital, Kobe, Japan, discusses findings from PRO-MOTE (NCT05931445), a multicenter open-label randomized trial evaluating electronic patient-reported outcome (ePRO) monitoring in Japanese patients with advanced solid tumors receiving systemic therapy. Despite high questionnaire completion rates, ePRO monitoring did not demonstrate superiority over usual care for global health status or overall survival. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Naomi Kiyota

Overcoming barriers to ePRO implementation in oncology practice
1:44
Overcoming barriers to ePRO implementation in oncology practice
Naomi Kiyota • 1 Jun 2026

Related Videos

Overcoming barriers to ePRO implementation in oncology practice
1:44
Overcoming barriers to ePRO implementation in oncology practice
Naomi Kiyota • 1 Jun 2026
Can genomic alterations be used to inform radiotherapy dosage?
1:37
Can genomic alterations be used to inform radiotherapy dosage?
Amy Xu • 31 May 2026
CLIO-8221: a novel anti-HER2 dual payload ADC conjugated to TOP1i and ATRi
4:36
CLIO-8221: a novel anti-HER2 dual payload ADC conjugated to TOP1i and ATRi
Timothy Yap • 4 Jun 2026
Werner helicase inhibitors: looking beyond immunotherapy for MSI tumors
10:50
Werner helicase inhibitors: looking beyond immunotherapy for MSI tumors
Timothy Yap • 4 Jun 2026
The content of VJOncology is intended for healthcare professionals